Indication and Implementation of Lipidapheresis, Rheopheresis, or Immunoadsorption (Lessons learnt from Germany's largest apheresis center)

Atherosclerosis Supplements

Volumn 10, Issue 5, 2009, Pages 137-141

  Heigl, Franz ^a   Hettich, Reinhard ^a   Lotz, Norbert ^a   Reeg, Harduin ^a   Eder, Bernadette ^a   Steckholzer Kroth, Karin ^a   Browatzki, Michael ^a   Harre, Kerstin ^a   Arendt, Rainer ^b  

^a Dres Heigl Hettich and Partner   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Apheresis center; Immunoadsorption; Lipid apheresis; Referral networks; Rheopheresis

Indexed keywords

LIPOPROTEIN A;

APHERESIS; APHERESIS CENTER; ARTICLE; GERMANY; HEALTH CARE FACILITY; HEALTH CARE UTILIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; IMMUNOADSORPTION; MULTIPLE SCLEROSIS; ORGANIZATIONAL STRUCTURE; PATIENT REFERRAL; PERCEPTION DEAFNESS; PRIORITY JOURNAL; RHEOPHERESIS; TREATMENT INDICATION;

ANTIBODIES; BLOOD COMPONENT REMOVAL; DELIVERY OF HEALTH CARE, INTEGRATED; GERMANY; HEALTH SERVICES ACCESSIBILITY; HEARING LOSS; HEMORHEOLOGY; HUMANS; HYPERLIPIDEMIAS; IMMUNOSORBENT TECHNIQUES; LIPIDS; MULTIPLE SCLEROSIS; PATIENT CARE TEAM; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 72749083644     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(09)71829-X     Document Type: Article

References (30)

1. Thompson G.R., Lowenthal R., and Myant R. Plasma exchange in the management of homozygous familial hypercholesterolemia. Lancet 1 (1975) 1208-1211
2. Thompson G.R., Myant N.B., Kilpatrick D., Oakley C.M., Raphael M.J., and Steiner R.E. Assessment of long-term plasma exchange for familial hyper cholesterolemia. Br. Heart J. 43 (1980) 680-688
3. Agishi T., Kaneko Y., Hasuo Y., Hayasaka Y., Sanaka T., Ota K., Amemiya H., Sugino N., Abe M., Ono T., Kawai S., and Yamane T. Double Filtration Plasmapheresis. Trans Am Soc Artif Intern Organs XXVI (1980) 406-411
4. Stoffel W., Borberg H., and Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolemia. Lancet 2 (1981) 1005-1007
5. Seidel D., and Wieland H. Ein neues Verfahren zur selektiven Messung und extrakorporalen Elimination von low density Lipoproteinen. J Clin Chem Clin Biochem 20 (1982) 684-685
6. Yokoyama S., Hayashi R., Kikkawa T., Tani N., Takada S., Hatanaka K., and Yamamoto A. Specific sorbent of apolipoprotein B-containing lipo- proteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits. Arteriosclerosis 4 3 (1984 May-Jun) 276-282
7. Bosch T., Schmidt B., Blumenstein M., and Gurland H.J. Lipid apheresis by hemoperfusion: in vitro efficacy and ex vico biocampatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif. Organs 17 (1993) 640-652
8. Seidel D. H.E.L.P. Report 1994 - 10 Years of Clinical Experience. MMV Medizin Verlag München (1994) 1-64
9. Mabuchi H., Koizumi J., Shimizu M., Kajinami K., Miyamoto S., Ueda K., and Takegoshi T. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 82 12 (1998 Dec 15) 1489-1495
10. Bosch T., and Keller C. Clinical effects of DALI-LDL-apheresis: beyond cholesterol reduction. Ther Apheresis and Dialysis 7 (2003) 343-346
11. Jaeger B.R., Richter Y., Nagel D., Heigl F., Vogt A., Roeseler E., Parhofer K., Ramlow W., Koch M., Utermann G., Labarrere C.A., and Seidel D. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nature Clinical Practice Cardiovascular Medicine 6 3 (2009) 229-239
12. Schuff-Werner P., Schütz E., Seyde W.C., Eisenhauer T., Janning G., Armstrong V.W., and Seidel D. Improved hemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin induced extraxorporeal LDL precipitation (H.E.L.P.). Eur J Clin Invest 19 (1989) 30-37
13. Mellwig K.P., van Buuren F., Schmidt H.K., Wielepp P., Burchert W., and Horstkotte D. Improved coronary vasodilatatory capacity by H.E.L.P. apheresis: comparing initial and chronic treatment. Ther Apher Dial 10 (2006) 510-517
14. 2 reactivity after heparin-mediated extracorporeal LDL precipitation (H.E.L.P.) in patients with coronary heart disease and hyperlipidemia. Stroke 30 (1999) 1802-1806
15. Schuff-Werner P. Clinical long-term results of H.E.L.P.-apheresis. Z. Kardiol 92 (2003) III28-III29
16. Suckfuell M. Fibrinogen and LDL-apheresis in treatment of sudden hearing loss: a randomised multicenter trial. Lancet 360 (2002) 1811-1817
17. Canis M., Heigl F., Hettich R., Osterkorn D., Osterkorn K., and Suckfuell M. Fibrinogen/LDL-Apheresis for treatment of sudden hearing loss: an observational study on 152 patients. HNO 56 (2008) 961-966
18. Heigl F., Hettich R., Suckfuell M., Luebbers C., Osterkorn D., Osterkorn K., and Canis M. Fibrinogen/LDL apheresis as successful second-line treatment of sudden hearing loss: a retrospective study on 217 patients. Atherosclerosis Supplements 10 (2009) 95-101
19. Pulido J.S., Sanders D., Winters J.L., and Klingel R. Clinical outcomes and mechanism of action for rheopheresis treatment of age-related macular degeneration (AMD). J Clin Apher 20 (2005) 185-194
20. Iizuka T., Takeda H., Inoue H., Miyamoto T., Ito H., Omura M., Tsuji H., Chiba S., and Nishikawa T. Clinical trial of low density lipoproteinapheresis for treatment of diabetic gangrene. Internal Medicine 36 12 (1997) 898-902
21. Schröder A., Fischer M., Meyer C., Ellrichmann G., Thöne J., Linker R.A., Chan A., and Gold R. Therapeutic plasmaexchange for steroid unresponsive multiple sclerosis relapses - a long-term follow-up observation including 35 patients. Akt. Neurol 36 (2009) 105-110
22. Moldenhauer A., Haas J., Wäscher C., Derfuss T., Hoffmann K.T., Kiesewetter H., and Salama A. Immunoadsorption patients with multiple sclerosis: an open-label pilot study. Eur J Clin Invest 35 8 (2005) 523-530
23. Thompson G.R., and HEART-UK LDL-Apheresis Working Group. Recommen dations for the use of LDL apheresis. Atherosclerosis 198 2 (2008 Jun) 247-255
24. Grundy S.M., Cleeman J.I., Merz C.N.B., Brewer H.B., Clark L.T., Hunninghake D.B., Pasternak P.C., Smith S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program. Adult Treatment Panel III Guidelines. Circulation 110 (2004) 227-239
25. Böhler S., Scharnagel H., Freisinger F., Stojakovic T., Glaesmer H., Klotsche J., Pieper L., Pittrow D., Kirch W., Schneider H., Stalla G.K., Lehnert H., Zeiher A.M., Silber S., Koch U., Ruf G., Wittchen H.-U., and Detect-Study Group. Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany. Atherosclerosis 190 2 (2007) 397-407
26. Baessler A., Fischer M., Hubauer U., Stark K., Hengstenberg W., Wiedmann S., Neureuther K., Holmer S., Mayer B., Schunkert H., and Hengstenberg C. Prognostische Implikationen einer fehlenden lipidsenkenden Therapie. Kohortenstudie mit Patienten mit Hyper- cholesterinämie nach Myokardinfarkt. MMW 148 III (2006) 125-132
27. Leitlinien der Deutschen Gesellschaft für Hals-Nasen-Ohren- Heilkunde: Hörsturz AWMF online: Wissensbasierte Leitlinien für Diagnostik und Therapie. http://web.archive.org/web/20071011010719/leitlinien.net/
28. Gold R., and Rieckmann P. Recent advances in the pathogenesis and immunotherapy of multiple sclerosis. Der Nervenarzt 78 Suppl 1 (2007) 15-26
29. Leitlinien für Diagnostik und Therapie in der Neurologie 4. überarbeitete Auflage 2008, S. 654 ff, ISBN 978-3-13-132414-6; Georg Thieme Verlag Stuttgart
30. Bewertung ärztlicher Untersuchung- und Behandlungsmethoden (BUB-Richtlinien) §§ 135 Abs 1 SGB V, Bundesanzeiger Nr 138 (S3321) v. 11.09.2008